Listen

Description

• 
  Sharon Cohen, MD, FRCPC, behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of lecanemab. 
  • Check out the full episode here: https://www.neurologylive.com/view/special-episode-lecanemab-approved-for-alzheimer-disease
    



• 
  Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida.
  • Check out the full episode here: https://www.neurologylive.com/view/episode-81-widening-therapeutic-window-parkinson-disease
    



• 
  Alberto Espay, MD, PhD, the division director and Research Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, and a professor of clinical neurology and rehabilitation medicine at the University of Cincinnati.
  • Check out the full episode here: https://www.neurologylive.com/view/episode-94-discussion-leqembi-lecanemab-approval-alzheimer-disease
    



• 
  Carolina Ferreira Atuesta, MD, MSc, a scientific researcher and clinical data manager at the Icahn School of Medicine at Mount Sinai.
  • Check out the full episode here: https://www.neurologylive.com/view/episode-82-managing-seizures-after-ischemic-stroke
    



• 
  Natalie Goedeker, CPNP, a nurse practitioner in neurology in the Neuromuscular Division at Washington University in St Louis.
  • Check out the full episode here: https://www.neurologylive.com/view/special-episode-tofersen-approved-sod1-als
    

• 
  1:20 – Cohen on the safety of lecanemab, including the 3 patient deaths reported in the supportive clinical trial program. 


• 
  6:25 – Hauser on the clinical advantages of IPX203, a potential new carbidopa/levodopa formulation for patients with Parkinson disease. 


• 
  9:20 – Espay on tempering expectations of lecanemab and other antiamyloid therapies in the treatment of Alzheimer disease.


• 
  13:20 – Atuesta on the lack of standardized methods for monitoring patients with poststroke seizures, including elders.


• 
  17:00 – Goedeker on the approval of gene therapy SRP-9001 for patients with Duchenne muscular dystrophy, the integration process, and safety considerations clinicians should be aware of.